|Drug Name||GPCR-targeted Project 011|
A monoclonal antibody agonist the G -protein coupled receptor G2A (GRP132) is being developed for the treatment of pancreatic cancer and pancreatic cancer ductal adenocarcinoma. GPR132 is a novel member of GPCRs.
|Target||G-protein coupled receptor G2A (GRP132)|
|Drug Modality||Monoclonal antibody|
|Mechanism of Action||G protein-coupled receptor agonists|
We look forward to hearing from you.